Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals reported new post hoc Phase 3 SOLOIST-WHF data showing that sotagliflozin’s efficacy and safety were consistent across baseline…
2,145$
-3,81%
Echtzeit-Aktienkurs Lexicon Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Lexicon Pharmaceuticals Inc. Aktie
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the…
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
…
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well
…
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win
…
Lexicon submits additional data for its diabetes drug to US FDA
Lexicon Pharmaceuticals said on Monday it had submitted supplementary data to the U.S. Food and Drug Administration to enhance the…
Lexicon Pharmaceuticals regains Nasdaq compliance By Investing.com
Lexicon Pharmaceuticals regains Nasdaq compliance…
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 30% and 23.52%, respectively, for the quarter ended March 2025. Do the…
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript
…
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 18.18% and 215.37%, respectively, for the quarter ended December 2024. Do the…
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025 Conference call and webcast at 8:00 a.m.…
Lexicon Pharmaceuticals to Participate in December Investor Conferences
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company…
Lexicon Appoints Ivan H. Cheung to Board of Directors
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan…
Lexicon Pharmaceuticals: Exklusive Partnerschaft mit Viatris bietet gemäß der Experten gigantisches Potenzial!
Lexicon Pharmaceuticals Inc. (LXRX) ist ein Biotech mit Fokus auf Behandlungsmethoden von schwerwiegenden chronischen Krankheiten. Das Unternehmen nutzt dabei die…
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three…
Lexicon Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation
…
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
…
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation…
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
…
Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
…
Lexicon Pharmaceuticals secures $250 million in private financing By Investing.com
Lexicon Pharmaceuticals secures $250 million in private financing…
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it…